Curi Bio lands over $4.4M in NIH grants for two projects
Curio Bio, a Seattle-based biotech company, received $4.4 million from the National Institutes of Health. The funding will be used to support two projects, one which focuses on Botox dosing and another which investigates Duchenne muscular dystrophy.
“These awards form the NIH represent a major validation of the importance of our innovative platforms in advancing pre-clinical research,” said Nicholas Geisse, CEO of Curi Bio. “We are honored to receive this recognition.”
Curi Bio’s work is centered around creating cardiac, disease and skeletal muscle models; it also provides researchers with data analyzation software. Including the recent grant funding, the NIH has provided over $12 million to Curi Bio’s efforts.